<DOC>
	<DOCNO>NCT03054883</DOCNO>
	<brief_summary>This observational study aim analyze effectiveness treatment patient newly dg . mantle cell lymphoma eligible high-dose therapy autologous stem cell transplantation . Scheme treatment : alternating cycle R-CHOP ( rituximab , cyclophosphamide , hydroxydaunomycin , oncovin , prednison ) R-AraC ( rituximab , cytarabin ) : R-CHOP / R-AraC / R-CHOP / R-AraC / R-CHOP / R-AraC . The study propose base previously publish data young patient , demonstrate improved outcome implementation Ara-C induction .</brief_summary>
	<brief_title>Observational Study Patients With Newly Diagnosed ( MCL ) Not Eligible High-dose Therapy</brief_title>
	<detailed_description>This observational study consider patient mantle cell lymphoma meeting basic inclusion criterion . The study enrol patient treat accord standard protocol use hematologic department . Scheme treatment : alternating cycle R-CHOP R-AraC : R-CHOP / R-AraC / R-CHOP / R-AraC / R-CHOP / R-AraC . Baseline procedure : - CT PET-CT ( positron emission tomography compute tomography ) start treatment , 3 cycle end treatment ( 6 cycle ) - bone marrow examination therapy , 3 cycle completion induction - maintenance rituximab base standard centre The study propose base previously publish data young patient , demonstrate improved outcome implementation Ara-C induction . Primary objective include response induction PET-CT PFS ( progression-free survival ) . Secondary objective include OS ( overall survival ) , prognostic significance minimal residual disease detection completion induction</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>confirm diagnosis MCL ( hematopathologic examination reference centre , evidence cyclin D1 translocation ( 11 ; 14 ) ) eligible highdose therapy autologous stem cell transplantation eligible RCHOP RCOEPbased therapy sign informed consent form study data processing non compliance patient CNS ( central nervous system ) involvement lymphoma ECOG ( Eastern Cooperative Oncology Group ) &gt; 3 active uncontrolled comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>minimal residual disease</keyword>
	<keyword>cytosine arabinoside</keyword>
</DOC>